Sean Whooley
Sean Whooley covers how money, strategy and regulation move through the medical device industry, focusing on the deals, earnings and approvals that shift the outlook for major device makers and their partners. He reports business news for MassDevice with an emphasis on concrete numbers, transaction terms and what they mean for company portfolios and market position.
Business-side coverage of medical devices
Whooley’s core subject is the business performance of device manufacturers, from large multinationals to high-growth specialists. His stories track revenue trends, segment growth and changes in guidance, with clear attention to which product lines or geographies drive the numbers. He covers capital allocation decisions such as investments, acquisitions and share repurchase plans, treating them as signals of how medtech leaders manage their balance sheets and bet on future technology.
He works across cardiovascular, orthopedics, neurotechnology, diabetes technology and surgical robotics rather than staying inside a single clinical silo. Company names, product families and device categories are treated as business units as much as therapies, and he writes in a way that lets readers situate each move inside the broader competitive landscape. Financial terms, timelines and stated strategic rationales are foregrounded, with clinical and technical detail included as needed to explain commercial stakes rather than for its own sake.
Deals, investments and portfolio strategy
A recurring strand in Whooley’s coverage is the structure and intent of medtech deals. He reports on equity investments, takeovers, joint ventures and licensing agreements, highlighting upfront payments, milestone structures, equity percentages and total deal values where disclosed. In stories such as Boston Scientific’s multibillion-dollar investment in TAVR developer MiRus paired with a large share repurchase plan, he treats a single news day as a window into both external growth strategy and internal capital return priorities.
He consistently frames transactions in terms of portfolio fit: which therapeutic area a target strengthens, how a new platform complements or disrupts an incumbent franchise, and whether the move extends a company into adjacent procedures or care settings. Emerging companies and technologies are introduced in that strategic context, with enough technical description to show why an incumbent is backing them and how the technology could scale commercially. His deal reporting helps readers see medtech not just as a pipeline of devices but as a set of evolving asset portfolios.
Earnings, guidance and market signals
Whooley also builds a steady record of earnings coverage for publicly traded device makers. His articles break out quarterly revenue, earnings per share, year-over-year growth and margin trends, calling out beats and misses against expectations when those are central to the story. He reports on management commentary around demand, supply chain, pricing, procedure volumes and R&D spending, showing how executives explain both short-term fluctuations and long-term bets.
Guidance changes, cost-cutting programs and restructuring plans are treated as important news in their own right, not as footnotes. He connects these moves to product launches, regulatory milestones and clinical data readouts when they influence the outlook for key franchises. Stock market reaction, when included, sits alongside operational detail rather than replacing it; the focus stays on what the numbers mean for business momentum and the ability to fund innovation.
Regulatory milestones and clinical data through a commercial lens
Regulatory clearances, approvals and key clinical trial results enter Whooley’s feed when they carry clear business implications. He covers FDA decisions, CE marks and other regulatory milestones with attention to label scope, indications, patient populations and any notable conditions that affect commercialization. Device performance data and trial outcomes are summarized in accessible terms, then tied directly to questions of reimbursement, adoption and competitive positioning.
Across this work, his distinguishing trait is consistency in treating clinical and regulatory news as part of a commercial story: how fast a device can reach market, how broadly it can be used and how it might reshape revenue mix for the companies involved. The result is coverage that serves readers who follow medtech as an industry and a business, not only as a set of technologies.
4 more business journalists.
Alex Bronzini-Vender
Alex Bronzini-Vender is a business reporter who focuses on how economic forces and corporate decisions shape specific communities and industries. He covers business for the Washington Monthly, writing reported pieces at the intersection of commerce and public life. His work reflects the magazine’s emphasis on linking markets and money to power, policy, and everyday experience. He treats business not as balance sheets and deals but as choices that affect local realities. In “Fear and Loathing in Palo Alto,” he uses a city tied to the tech sector to examine how a powerful industry influences a community. He grounds his business beat in on-the-ground consequences rather than treating corporate and financial developments in isolation.
Alex Smith
Alex Smith focuses on the business impact of enterprise technology, with a distinctive emphasis on AI literacy and skills rather than technical specifications. They write for Technology Record, covering how artificial intelligence and cloud platforms from major providers are turned into concrete programmes for organisations and governments. Their beat sits at the junction of business strategy, national digital policy and large-scale technology partnerships. They report on national AI literacy programmes and public–private partnerships, showing how policy choices, vendor capabilities and skills gaps intersect. On the business beat, they treat AI and cloud as tools for competitiveness, workforce readiness and participation in a data-driven economy. Their concise, announcement-led reporting highlights who is partnering with whom, what programme is being launched, which technologies underpin it and how it changes capability on the ground for executive readers.
Alison Durkee
Alison Durkee focuses on how law, regulation and politics create business risks for major companies and industries. She is a reporter at Forbes, where she writes news-driven explainers on complex legal and regulatory developments and their impact on corporate strategy, reputation and markets. Her coverage centers on companies under scrutiny, especially in technology and other high-growth sectors, and tracks trials, investigations and fast-changing policy fights. She breaks down lawsuits, inquiries and regulatory moves into clear parts, grounded in timelines, filings and official actions. She reports on generative artificial intelligence and other emerging technologies as tests of legal frameworks and corporate risk management, explaining how issues like intellectual property, safety compliance, consumer protection and governance can reshape product roadmaps, partnerships and investor expectations.
Alyson Shontell
Alyson Shontell covers business through the lens of leadership, using in-depth conversations with powerful executives and founders to show how their decisions shape companies, markets, and public life. She is editor in chief at Fortune, overseeing coverage across the masthead while continuing to write selected high-impact pieces. Her core work is long, reported interviews and profiles of CEOs of large companies, dominant tech firms, and fast-growing startups. She focuses on how leaders think, manage risk, make unconventional calls, and handle crises, culture, and the future of work. Her subjects include corporate chiefs, startup founders, and political figures treated as executives. She probes operating detail, governance, internal culture, and trade-offs around growth, disruption, and workplace models, using concrete examples and direct, accessible prose that foregrounds the subject’s voice while pressing for specifics.